Effect of active immunization against luteinizing hormone‐releasing hormone on the androgen‐sensitive Dunning R3327‐PAP and androgen‐independent Dunning R3327‐AT2.1 prostate cancer sublines

Fuerst, Johannes; Fiebiger, Eduard; Jungwirth, A.; Mack, D; Talwar, Pran G.; Frick, J.; Rovan, E.

doi:10.1002/(sici)1097-0045(19970701)32:2<77::aid-pros1>3.3.co;2-g

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dunning tumor clones adopted to rats were used for this purpose. The growth ofthe androgen-dependent cancer cells was markedly inhibited in the LHRH-vaccinated rats (63). The inhibition was dne to reduction of the mitotic index and not due to enhanced apoptosis.…”

Section: Carcinoma Ofthe Prostatementioning

confidence: 93%

Vaccines and passive immunological approaches for the control of fertility and hormone‐dependent cancers

1999

Immunological Reviews

View full text Add to dashboard Cite

Reviewed here is the development of a vaccine against the human chorionic gonadotropin that prevents pregnancy in sexually active women without impairment of ovulation or derangement of menstrual regularity. Also reviewed are the vaccines inducing antibodies against the luteinizing hormone-releasing hormone, which have immunotherapeutic potential in prostatic hypertrophy and other sex hormone-dependent male and female cancers. The adoption of passive immunization using humanized recombinant antihormone antibodies is advocated for assured efficacy and safe, prompt therapeutic action.

show abstract

Section: Carcinoma Ofthe Prostatementioning

confidence: 93%

Vaccines and passive immunological approaches for the control of fertility and hormone‐dependent cancers

1999

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…Inference was drawn that at this stage the cancer had become androgen-independent. Studies in rats implanted with androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 sublines have shown that LHRH vaccine suppresses effectively the growth of androgen-sensitive tumors and has partial but not full effect on androgenindependent Dunning tumor cells [5].…”

Section: Introductionmentioning

confidence: 99%

A monoclonal antibody cytolytic to androgen independent DU145 and PC3 human prostatic carcinoma cells

Gp¹,

Gupta²,

Gupta

et al. 2001

Prostate

View full text Add to dashboard Cite

Background While a range of therapeutic products is available for androgen‐dependent prostatic cancer, no specific intervention modality exists for androgen‐independent prostatic cancer. The objective of this research was to explore whether epitopes exist on androgen‐independent prostatic DU145 cancer cells, which could be susceptible to cytotoxic action of specific antibodies. Methods Hybrid cell clones were developed by immunization of mice with DU145 cells and tested for immunoreactivity by solid phase EIA and cytotoxicity in vitro on DU145 in the presence of the complement, employing colorimetric quantitation by MTS (3‐ (4‐, 5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐(4‐sulfophenyl)‐2H‐tetrazolium). Binding and cytotoxicity studies were also carried out by flow‐cytometry. Results Of 15 stabilized clones immunoreactive with DU145 cells, one monoclonal antibody (mAb 730) manifested cytotoxicity on DU145 cells. Approximately 80% of cells in the DU145 cell line were susceptible to lysis with this antibody at saturating levels. This figure corresponded quantitatively to the number of cells binding with this antibody as determined by Flow‐cytometry. Staining with ethidium monoazide bromide (EMA) showed that the cell binding the antibody was also the one killed by the antibody in the presence of the complement. MAb 730 was also cytotoxic to PC3, another androgen‐independent human prostatic cancer cell line. This antibody is devoid of classical autoantibody reactivities and does not react with normal human liver, thyroid, kidney, pancreas, and adrenal tissues, as determined by immunofluorescence. Also, it shows negative immuno‐reactivity to benign glandular tissue but is observed to positively react with neoplastic prostate tissue. Conclusions Epitopes exist on androgen‐independent prostatic cancer cells that are susceptible to cytolysis by monoclonal antibodies and these could be investigated for potential immunotherapy. Prostate 46:207–213, 2001. © 2001 Wiley‐Liss, Inc.

show abstract

“…Active immunization against LHRH was tested in rats [78]. Its effect on the growth characteristics and histology of subcutaneously implanted androgen-sensitive and androgenindependent tumors was studied.…”

Section: Cancer Vaccines Targeting the Hormone Lhrh/gnrhmentioning

confidence: 99%

Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment

Gonzalez

Lage

2007

CCDT

View full text Add to dashboard Cite

One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, so that the concept of hormone-dependence can be extended to growth factors deprivation. Hormone deprivation has been therapeutically achieved up to now by surgical, radiation and chemical means. However, the immune system usually can be manipulated to recognize hormones and growth factors, and in fact some autoimmune diseases exists involving autoantibodies against hormones. The idea of inducing a deprivation of hormones and growth factors by active immunizations is appealing, and initial evidence about the feasibility of this approach is starting to appear in the literature. Clinical trials have been initiated using immunization with human chorionic gonadotrophin (hCG), gastrin, luteinizing hormone releasing hormone (LHRH) / gonadotropin releasing hormone (GnRH) and epidermal growth factor (EGF). Preliminary data already show that antibody titers can be elicited, which results in a decrease in the concentration of a given hormone or growth factor. Both the antibody titers and the decrease in the hormone level are related to survival. This immunological approach for hormone and growth factor deprivation creates the possibility of chronic management of advanced cancer patients.

show abstract

Effect of active immunization against luteinizing hormone‐releasing hormone on the androgen‐sensitive Dunning R3327‐PAP and androgen‐independent Dunning R3327‐AT2.1 prostate cancer sublines

Cited by 3 publications

References 0 publications

Vaccines and passive immunological approaches for the control of fertility and hormone‐dependent cancers

Vaccines and passive immunological approaches for the control of fertility and hormone‐dependent cancers

A monoclonal antibody cytolytic to androgen independent DU145 and PC3 human prostatic carcinoma cells

Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment

Contact Info

Product

Resources

About